Christopher B. Jones, MD

Special Interests

I am a clinical hematology/oncology physician. I see all types of hematologic disorders and every type of cancer. I am interested in cooperative group oncology clinical trials to promote best practice in oncology to achieve optimal results.

Awards & Recognition

2005-2006: UTHSCA Outstanding Faculty Award for 3rd year Medical Student
2005: Bronze Star, Operation Iraqi Freedom II
2000: William J Uphouse Award for most compassionate physician
 

Board Certification

2003: Medical Oncology
2003: Hematology
2000: Internal Medicine

Professional Memberships

ASCO
American Society Hematology

Publications

Schwartz Garry H and Jones Christopher B. et al. A Phase I and Pharmacokinetic Study of Non-polyglutamatible Thymidylate Synthase Inhibitor ZD9331 and Docetaxel in Patients with Advanced Solid Malignancies. Investigational New Drugs 22: 437-448, 2004.

Mita AC, Hammond LA, Jones CB et al. Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors. Clinical Cancer Research. 12: 5207-5215, 2006.

R.F. Setlik, G. Preston, C.B Jones et al. A Phase I Study of the Effects of Hepatic Impairment on the Pharmacokinetic (PK) and Safety of Satraplatin in Patients with Refractory Non-Hematologic Cancer. ASCO Clinical Proceedings, Abstract #2045, 2006

Shumway NM, Jones CB, and Terrazzino S. Randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting. ASCO Clinical Proceedings, Abstract 9633, 2009

Teaching & Professional Positions

2013-2015: Levine Cancer Institute, Leukemia Committee
2013-2015: Levine Cancer Institute, Upper/Lower GI Cancer Committee
2013-2015: Levine Cancer Institute, Genetic Committee
2007-2008: Chief, Hematology/Oncology Services, Brooke Army Medical Center
2006-2008: Assistant Program Director, SAUSWEC Hematology/Oncology Fellowship
2004-2005: Chief Medical Services, 115th Field Hospital

Conflicts of Interest

National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations.